Skip to main content
. 2009 Jan;58(1):250–259. doi: 10.2337/db08-0392

FIG. 4.

FIG. 4.

Hepatic protein and gene expression analysis. Total protein and RNA were extracted from frozen liver samples of mice fed standard diet and administered vehicle (open bars, SD), fed high-fat diet and administered vehicle (open bars, HFD), FGF21 (striped bars; 0.1, 1, and 10 mg · kg−1 · day−1 doses), or rosiglitazone (black bars; ∼4 mg · kg−1 · day−1) for 6 weeks. Western analyses and RT-PCRs were conducted on pooled protein and RNA extracts (n = 5 per group). A: FGF21 reduced the amount of mature SREBP-1 without changing its precursor content in liver. Vehi, vehicle; Rosi, rosiglitazone. B: FGF21 reduced protein expression levels of total ACC, FAS, and PPARγ in liver. C: FGF21 reduced mRNAs encoding enzymes involved in hepatic lipogenesis without changing SREBP-1 mRNA expression. GK, glucokinase; PK, pyruvate kinase; SCD1, stearoyl-CoA desaturase 1; Elovl6, long-chain fatty acid elongase 6; DGAT1 and MOGAT2, diacylgycerol and monoacyglycerol acyltransferases. D: FGF21 reduced mRNA expression of PPARγ and its target genes, aP2 and CD36, in liver. E: FGF21 reduced glucose-6-phosphatase (G6Pase) mRNA expression.